Monitoring Cytotoxic Effects In Non‐Cancerous Cells via Docetaxel

Abstract

Listen

Translate article

Therapeutic chemotherapy drugs are known to induce cytotoxicity in both non‐cancerous cells and in malignant cells. However, it is still unknown if the chemotherapy drug Docetaxel induces cytotoxic events in non‐cancerous cells. Our approach to measuring cytotoxic events was H&E staining (hematoxylin and eosin) followed by immunohistochemistry (IHC) with Estrogen Receptor α (ERα), Androgen Receptor α (ARα) or Ki‐67 antibodies to determine if the cytotoxicity occurred in cancerous or non‐cancerous cells. In the MCF7 breast cancer cell line, chemotherapy drug Docetaxel induced cytotoxic effects in 44.20% of malignant breast cancer cells and 34.86% in non‐malignant cells as classified according to their response to the ERα antibody with a standard deviation of 26.89%. Patient derived prostate cancer cells grown in mice generated from the MDA‐MB‐231 cell line were also treated with Docetaxel. An average of 28.3% of prostate cancer cells exhibited ARα monoclonal antibody sensitivity, and 28.3% of prostate cancer cells displayed cytotoxic effects after administration of Docetaxel with a standard deviation of 34.3%. In conclusion, Docetaxel was shown to induce cytotoxic effects in both in prostate cancer cells and non‐malignant cells however it induced a greater toxic effect in nonmalignant breast cancer cells.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.